SEQUENOM announces sale of three additional MassARRAY systems, increasing customer installed base of systems to 29 worldwide
San Diego (ots-PRNewswire) -
SEQUENOM(TM), Inc. (Nasdaq: SQNM) today announced that it has sold three additional MassARRAY systems, increasing the Company's installed base of systems at customer sites to 29 worldwide. The three additional sales include the purchase of a second system by the Whitehead Institute/Centre for Genome Research, the world's largest public genome research centre, and initial purchases by Galileo Genomics and an undisclosed party.
SEQUENOM continues to sell MassARRAY systems to leading genomic and diagnostic companies and institutions, capitalising on the momentum that started with the product's commercial launch in early 2000. The MassARRAY system is the Company's proprietary platform for high-throughput analysis of genetic variations, or single nucleotide polymorphisms (SNPs), and the cornerstone of SEQUENOM's Systems business unit. The system is also the enabling platform used by the Company's Genomics business unit for identifying SNPs and genes that significantly impact health.
"The marketplace has confirmed that our MassARRAY system is the platform of choice for groups serious about undertaking large-scale genetic studies," said Toni Schuh, Ph.D., SEQUENOM's President and Chief Executive Officer. "In the past year, our systems business has seen demand steadily increase as the leading genomics companies and research institutions from around the world discover the advantages of our technology and services.
"Our customers also recognise that we provide a comprehensive solution for determining the medical utility of SNPs and genes," continued Schuh. "This is enabled by our ability to conduct full genome screens, which is the analysis of many genes in many people. In addition to the MassARRAY system, our automated assay design process, the power to combine or pool hundreds of samples in a single reaction to determine the frequency of genetic markers and an in-house DNA bank for a control population make such projects a reality today."
About the Whitehead Institute
The Whitehead Institute is a non-profit, independent basic research and teaching institution recognised worldwide for pathfinding programs in cancer and AIDS research, developmental biology, structural biology, infectious disease, and genetics. The Institute's mission is to improve human health and welfare and extend the boundaries of knowledge for future generations.
About Galileo Genomics
Galileo Genomics is a population genomics company dedicated to the discovery of disease-susceptibility genes in common human diseases through the application of genetics to founder populations using cutting-edge technologies. Galileo's research relies on the study of genetic data collected from the Quebec Founder Population, a population of 6 million distantly related individuals descended from a small group of roughly 2,500 common ancestors that arrived from France between 1608 and 1760.
SEQUENOM is leading a worldwide effort to identify genes and genetic variations with significant impact on human health. Using its innovative technologies, information and scientific strategy, the Company is rapidly translating data generated from the Human Genome Project into medically important applications. Breaking through the limitations of traditional research, SEQUENOM's MassARRAY technology, assay database, population genetics approach and ability to perform full genome screens are generating results that position SEQUENOM and its customers and collaborators to quickly capture novel leads to utilise in new genetics-based diagnostics, drugs and therapies.
All statements in this press release that are not historical are forward-looking statements within the meaning of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are subject to factors that could cause actual results to differ materially for SEQUENOM from those projected. Those factors include risks and uncertainties relating to technological approaches, dependence on collaborative partners, the specific results generated and successful performance under these and other collaborative agreements, product development, manufacturing, market acceptance, cost and pricing of SEQUENOM products, competition, the intellectual property of others, patent protection and other risk factors discussed from time to time in SEQUENOM's reports and filings with the Securities and Exchange Commission, including SEQUENOM's Annual Report on Form 10-K for the year ended December 31, 1999 and most recent Quarterly Report on Form 10-Q. SEQUENOM expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in SEQUENOM's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
ots Original Text Service: SEQUENOM, Inc. Internet: www.newsaktuell.ch
Abigail Devine, APR, Investor Relations of SEQUENOM, Inc.,
Tel. +1 858 202 9032, e-mail: email@example.com; or
media, Renee Connolly of Noonan/Russo Communications,
Tel. +1 212-696-4455, ext. 227,e-mail: firstname.lastname@example.org,
for SEQUENOM, Inc.
Company News On-Call:
fax, +1 800 758-5804, ext. 124192